Zarxio Approval History
Zarxio (filgrastim-sndz) is a leukocyte growth factor biosimilar to the reference product Neupogen, indicated for the treatment of neutropenia associated with chemotherapy.
Development History and FDA Approval Process for Zarxio
|Mar 6, 2015||FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)|
|Jan 7, 2015||Sandoz Biosimilar Filgrastim Recommended for Approval|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.